Escolar Documentos
Profissional Documentos
Cultura Documentos
2
Key Concepts
Chronic Kidney Disease (CKD) US Prevalence
~19 million
The Kidney Disease Outcomes Quality Initiative
(K/DOQI)
CKD risk factor categories
susceptibility factors
initiation factors
progression factors
3
Key Concepts
Mechanisms of CKD progression
reduction in kidney mass
glomerular hypertension
intratubular proteinuria
5 CKD stages based on
structural damage
renal function
4
Key Concepts
Serum creatinine (SCr):
unreliable marker of kidney function in select patients
elderly
malnourished
children
estimate GFR
used to evaluate rate of disease progression
5
Key Concepts
Stage 5 CKD symptoms:
asterixis
pruritus
dysgeusia
nausea, vomiting
anorexia, weight loss
susceptibility to bleeding
Signs/symptoms of uremia foundational to decision to
implement kidney replacement therapy
6
Key Concepts
Titrate ACEI/ARB to maximal suppression of urinary
albumin excretion for DM patients with persistent
microalbuminuria despite intensive insulin therapy
even without HTN
ACEIs/ARBs: key pharmacologic treatments
hemodynamic & BP reduction effects limit kidney
disease progression
7
Key Concepts
Supportive therapies may slow CKD progression
dietary protein restriction
lipid-lowering medications
smoking cessation
anemia management
Limit progression with hyperglycemia & HTN
treatment
8
Epidemiology
Worldwide public health problem: “silent epidemic “
CKD affects ~5% of adult US population
CKD defined as SCr > 1.2 to 1.5 mg/dL
The Third National Health And Nutritional Examination
Survey (NHANES III)
nationally representative sample of US adult population
> 10.9 million people have SCr > 1.5 mg/dL
CKD prevalence ~10.9% of US population age > 20 yrs (19
million) if microalbuminuria & proteinuria included
Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation,
classification, and stratification. Ann Intern Med 2003;139:137–147.
Jones CA, McQuillan GM, Kusek JW, et al. Serum creatinine levels in the U.S. population: Third National Health and Nutrition 9
Examination Survey. Am J Kidney Dis 1998;32:992–999.
Etiology
Susceptibility factors:
advanced age
low income or education
racial/ethnic minority status
reduced kidney mass
low birth weight
family history
Useful for identifying populations at high risk for CKD
10
Etiology
Initiation factors:
result in direct kidney damage
modifiable by pharmacologic therapy
DM, HTN, autoimmune diseases, polycystic kidney
disease, systemic infections, urinary tract infections,
urinary stones, lower urinary tract obstructions, drug
toxicity
Most common causes of CKD in the US:
diabetes mellitus
HTN
glomerular diseases
11
Etiology
Progression factors:
associated with further kidney damage
evident as increased decline in kidney function in patients
who already have kidney damage
proteinuria, elevated BP, smoking
Predictors of progressive CKD:
persistence of underlying initiation factors
DM
HTN
glomerulonephritis
polycystic kidney disease
12
The Kidney
2 million nephrons
filter
reabsorb
excrete solutes
excrete water
Primary regulator
Na+ & H2O balance
acid–base homeostasis
Hormone production necessary for RBC synthesis &
Ca2+ homeostasis
13
Pathophysiology
Heterogeneous causes
diabetic nephropathy: glomerular mesangial expansion
hypertensive nephrosclerosis: kidney's arterioles have arteriolar
hyalinosis; renal cysts present in polycystic kidney disease
initial structural damage may depend on the 1˚ disease
Progressive nephropathies result in irreversible renal
parenchymal damage & ESRD
Key pathway elements
loss of nephron mass
glomerular capillary hypertension
proteinuria
14
15
Pathophysiology
Initiation factor exposure
remaining nephrons hypertrophy to compensate for loss
of nephron mass and renal function
compensatory hypertrophy may be adaptive
hypertrophy may lead to intraglomerular hypertension
possibly mediated by angiotensin II
16
Kidney Disease/Injury
1. acute renal failure:
rapid loss of kidney function
hours to weeks
50% increase in SCr (> 0.5 g/dL)
2. chronic kidney disease:
also called chronic renal insufficiency, progressive kidney
disease
progressive loss of function
months to years
gradual replacement of normal kidney architecture with
interstitial fibrosis 17
Kidney Disease Classification
National Kidney Foundation's (NKF) Kidney Dialysis
Outcomes & Quality Initiative (K/DOQI) CKD
classification system (stages 1 to 5)
Categories based on structural kidney damage &/or
functional changes in GFR for > 3 months
stage 1: mild structural changes evidenced by
microalbuminuria with "normal" kidney function
stage 5: analogous to end stage renal disease: dialysis or
kidney transplantation may be necessary
increasing number: more advanced stage of disease
SCr: inaccurate index of GFR
18
Kidney Disease
Normal adult kidney function
GFR ~120 mL/min/1.73 m2
Can diagnose CKD when GFR > 90 mL/min/1.73 m2
based on:
proteinuria
hematuria
evidence of structural damage from kidney biopsy
19
CKD Stages
a c
Stage GFR Prevalence
b
1 > 90 10,500,000
2 60–89 7,100,000
3 30–59 7,600,000
4 15–29 400,000
d
5 < 15 300,000
a Glomerular filtration rate (mL/min/1.73 m2) b CKD can be present with
normal/near normal GFR if other markers of kidney disease are present
c Based on elevated albumin to creatinine ratio dincludes patients on dialysis
DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM: Pharmacotherapy: A Pathophysiologic Approach, 7th Edition: 20
http://www.accesspharmacy.com
Presentation/Diagnosis
Development & progression may be insidious
CKD diagnosis
measure SCr, estimate GFR
assess urine for protein &/or albumin
CKD stages 3, 4, 5 require additional workup
anemia
CV disease
metabolic bone disease
malnutrition
fluid & electrolyte disorders
21
CKD Risk Factors
Susceptibility
Advanced age
Reduced kidney mass and low birth weight
Racial/ethnic minority
Family history
Low income or education
Systemic inflammation
Dyslipidemia
Initiation
Diabetes mellitus
Hypertension
Glomerulonephritis
Progression
Glycemia (among diabetic patients)
Hypertension
Proteinuria
Smoking
Obesity
DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM: Pharmacotherapy: A Pathophysiologic Approach, 7th Edition: 22
http://www.accesspharmacy.com
Diabetes
Not all individuals with diabetic nephropathy progress
to stage 5 CKD; however, high lifetime risk
Multiple Risk Factor Intervention Trial (MRFIT)
prospective study
> 300,000 individuals screened
~3% of DM patients develop stage 5 CKD
DM subjects: 12-fold greater RR of stage 5 CKD
increased risk of nondiabetic CKD causes
suggests underlying genetic susceptibility
Brancati FL, Whelton PK, Randall BL, Neaton JD, Stamler J, Klag MJ. Risk of end-stage renal disease in diabetes mellitus: 23
A prospective cohort study of men screened for MRFIT. Multiple Risk Factor Intervention Trial. JAMA 1997;278:2069–2074.
Diabetes & CKD
Type 1 DM patients: 40% lifetime risk of developing CKD
Type 2 DM patients: 50% lifetime risk of developing CKD
Greater prevalence of type 2 DM compared to type 1
10:1 ratio in most countries
majority of CKD due to DM among type 2 DM patients
Hasslacher C, Ritz E, Wahl P, Michael C. Similar risks of nephropathy in patients with type I or type II diabetes mellitus. 24
Nephrol Dial Transplant 1989;4:859–863.
Hypertension
Increases CKD risk
Exact role as cause/consequence debated
Kidney has a role in HTN development/modulation
Generally develops concomitantly with progressive
kidney disease
Early HTN treatment to aggressive goals slows CKD
progression
25
Hypertension
Multiple Risk Factor Intervention Trial
1˚ prevention
evaluated effect of an intervention on CHD mortality
16 year follow-up
lifetime risk of stage 5 CKD for patients with HTN: 5.6%
risk varied dramatically by BP
0.33% SBP 140 to 150 mm Hg &/or DBP 90 to 100 mm Hg
4.5% for SBP > 180 mm Hg or DBP > 110 mm Hg
26
Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996;334:13–18.
Hypertension
Elevated BP increases risk for developing CKD
Prospective study (n=316,675) managed care patients
increased stage 5 CKD risk in patients with elevated
baseline BP
odds ratio for CKD development:
2.0 (95% confidence interval [CI] 1.6 to 2.5) for SBP 120 to 129
mm Hg & DBP 80 to 84 mm Hg diastolic
4.3 (95% CI 2.6 to 6.9) for SBP > 210 mm Hg or DBP >120 mm
Hg compared to BP SBP < 120 and DBP < 80 mm Hg
Perneger TV, Nieto FJ, Whelton PK, Klag MJ, Comstock GW, Szklo M. A prospective study of blood pressure and serum creatinine.
Results from the "Clue" Study and the ARIC Study. JAMA 1993;269:488–493.
Hsu CY, McCulloch CE, Darbinian J, Go AS, Iribarren C. Elevated blood pressure and risk of end-stage renal disease in subjects 27
without baseline kidney disease. Arch Intern Med 2005;165:923–928.
Glomerulonephritis
Glomerular diseases: initiation factors with variable
epidemiology, pathophysiology
Goodpasture's disease or Wegener's granulomatosus
may progress rapidly to stage 5; cause ARF
Immunoglobulin (Ig) A nephropathy, membranous
nephropathy, focal segmental glomerulosclerosis, lupus
nephritis, & others more indolent cause of CKD
chronic glomerular diseases progress at variable rates
loss of GFR 1.4 to 9.5 mL/min/year
28
Interesting, right?
This is just a sneak preview of the full presentation. We hope
you like it! To see the rest of it, just click here to view it in full
on PowerShow.com. Then, if you’d like, you can also log in to
PowerShow.com to download the entire presentation for free.